SCHEMBL6906114

SCHEMBL6906114

c1ccc(Nc2ncc3nccc-3[nH]2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.46
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
TAAR1 Q96RJ0 1/20 0.42
MAPT P10636 3/20 0.41
GAA P10253 1/20 0.41
GFER P55789 1/20 0.41
PRKCD Q05655 2/20 0.38
ABL1 P00519 1/20 0.38
EGFR P00533 1/20 0.38
PRKCA P17252 1/20 0.38
AURKA O14965 2/20 0.38
PIM1 P11309 2/20 0.38
CDK2 P24941 2/20 0.38
CHEK1 O14757 1/20 0.38
IKBKB O14920 1/20 0.38
NPC1 O15118 1/20 0.38
PDPK1 O15530 1/20 0.38
CHEK2 O96017 1/20 0.38
PRKCG P05129 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3604812 0.75
SCHEMBL15380931 0.73 MEN1 (0.42) POLBMEN1KMT2ATAAR1MAPT
SCHEMBL2231249 0.71 POLB (0.44) POLBMEN1KMT2ATAAR1MAPT
SCHEMBL2282586 0.70 TAAR1 (0.59) POLBMEN1KMT2ATAAR1MAPT
SCHEMBL2580017 0.70 SCN2A (0.63)
SCHEMBL29155145 0.67 CDC7 (0.44) GAAPRKCDPIM1CDK2CDK1
SCHEMBL994128 0.67 MEN1 (0.50) POLBMEN1KMT2ATAAR1MAPT
SCHEMBL2281476 0.67 MEN1 (0.50) POLBMEN1KMT2ATAAR1MAPT
SCHEMBL11275747 0.67 POLB (0.46) POLBMEN1KMT2ATAAR1MAPT
SCHEMBL10502996 0.66 MEN1 (0.45) POLBMEN1KMT2ATAAR1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1453518-A1 PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DISORDERS OF NON-HUMAN MAMMALS Boehringer Ingelheim International GmbH (DE) 2004-09-08 EP disclosed
US-20030162796-A1 Pharmaceutical composition for the treatment of disorders of non-human mammals BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2003-08-28 US disclosed
WO-2003030910-A1 PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DISORDERS OF NON-HUMAN MAMMALS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2003-04-17 WO disclosed
EP-1300146-A1 Pharmaceutical composition for the treatment of animal mammary tumors Boehringer Ingelheim International GmbH (DE) 2003-04-09 EP disclosed
EP-1297184-A1 METHOD FOR MONITORING THE EFFECT OF CANCER THERAPIES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2003-04-02 EP disclosed
US-20020102685-A1 Novel use of inhibitors of the epidermal growth factor receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH 2002-08-01 US disclosed
US-20020042072-A1 Method for monitoring the effect of cancer therapies BOEHRINGER INGELHEIM GMBH (DE) 2002-04-11 US disclosed
WO-2002002120-A1 NOVEL USE OF INHIBITORS OF THE EPIDERMAL GROWTH FACTOR RECEPTOR BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2002-01-10 WO disclosed
EP-1170378-A1 Method for monitoring the effect of cancer therapies Boehringer Ingelheim International GmbH (DE) 2002-01-09 EP disclosed
EP-1170011-A1 Novel use of inhibitors of the epidermal growth factor receptor Boehringer Ingelheim International GmbH (DE) 2002-01-09 EP disclosed
WO-2002000925-A1 METHOD FOR MONITORING THE EFFECT OF CANCER THERAPIES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2002-01-03 WO disclosed